Table 1.
Demographic and Clinical Patient Characteristics
| Clinical Characteristics | |
|---|---|
| Number of patients, n (%) | 29 (100%) |
| Age, years, median (range) | 47 (range 27–86) |
| Gender, n (female/male) | 19/10 |
| MPN subtype, n (%) | |
| PV/PV-MF | 20 (70.0%) |
| PMF | 3 (10.3%) |
| ET | 3 (10.3%) |
| Isolated JAK2/CALR mutation | 2 (6.9%) |
| Driver mutation, n (%) | |
| JAK2V617F | 26 (89.7%) |
| CALR | 1 (3.4%) |
| MPL | 1 (3.4%)* |
| MPN Therapy, n (%) | |
| Phlebotomy | 11 (37.9%) |
| Aspirin | 10 (34.5%) |
| Hydroxyurea | 13 (44.8%) |
| Ruxolitinib | 4 (13.8%) |
| Interferon alpha | 1 (3.4%) |
| Etiology of portal hypertension, n (%) | |
| BCS | 21 (72.4%) |
| PVT | 6 (20.7%) |
| Other SVT | 5 (17.2%) |
| EMH | 5 (17.2%) |
| NRH | 2 (6.9%) |
| Multifactorial | 9 (31.0%) |
| TIPS indication, n (%) | |
| Ascites | 25 (86.0%) |
| Esophageal varices | 15 (51.7%) |
| Ascites and esophageal varices | 13 (44.8%) |
| Intestinal ischemia | 2 (6.9%) |
| Liver failure | 2 (6.9%) |
| Hepatic hydrothorax | 1 (3.4%) |
| Anticoagulation, n (%) | |
| Coumadin | 20 (69.0%) |
| Low-molecular weight heparin | 5 (17.2%) |
| Fondaparinux | 5 (17.2%) |
| None | 4 (13.8%) |
Abbreviations: PV, polycythemia vera; PV-MF, post-PV myelofibrosis, PMF, primary myelofibrosis; ET, essential thrombocythemia; BCS, Budd-Chiari syndrome; PVT, portal vein thrombosis; SVT, splanchnic vein thrombosis; EMH, extramedullary hematopoiesis; NRH, nodular regenerative hyperplasia. n, number of patients with the listed clinical characteristic.
*
Patient also had concurrent JAK2V617 mutation.